$RLFTF DD post by Vader: Until now, there have been NO effective COVID treatments. Although drugs like dexamethasone, Remdesivir and Monoclonal antibodies/convalescent plasma have been approved for fighting COVID, these drugs have minimal efficacy, are expensive to produce and difficult to transport. In fact, the World Health Organization doesn’t even recommend using Remdesivir because there is no proven mortality benefit. (https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients)
Relief Therapeutics, a penny stock trading under RLFTF is a small Swiss biotech that owns the rights to synthetic vasoactive intestinal peptide (VIP). The substance is also known by the trademarked names, aviptadil, RLF-100 and Zyesami. VIP is a peptide. Peptides are small molecules which are produced by the body and have systemic effects. In proof that good things come from small packages, consider the fact that the most famous peptide is insulin.
As of 2/23/21, Relief Therapeutics and their profit-sharing partner, NeuroRx have announced positive data related to their recent phase 3 trial. The results were STATISTICALLY SIGNIFICANT for patients high flow O2. These patients get out of the hospital faster BY 10 DAYS! This means we now have an effective COVID 19 therapy for patients in the ICU. It improves oxygenation, gets them out of the hospital fast and prevents progression to mechanical ventilation.
Based on the favorable results, one can reasonably conclude that:
Submission of phase 3 data has already occurred to the FDA in anticipation of possible EUA
OWS has received a copy of this favorable phase 3 data with the expectation that their pending contract (30k initial treatment purchase and purchase of 100k treatments quarterly) may rapidly be approved.
Rapid adoption in ICUs nationwide can be anticipated given the improvement in survival, oxygenation, days on mechanical ventilation and days in the ICU overall
Peer reviewed publication of results in The Lancet and other journals
WHY IS VIP/Aviptadil/RLF-100/Zyesami SO GREAT AT TREATING COVID?
Well, for one, VIP has five separate mechanisms of action.
It directly inhibits viral replication
It has broad anti-inflammatory effects with decrease in II 6, cytokines and TNF
It causes surfactant production
It has direct bronchodilator effects to improve pulmonary blood-flow and increase the V/Q ratio (level of oxygenation)
Blocks apoptosis (cell death)
Additionally, VIP is highly effective at treating COVID because it is not dependent on the protein spike that most current vaccines work on. To this end, VIP efficacy is not affected by the current coronavirus mutations (London strain, South African strain, etc) which are beginning to demonstrate increased mortality and vaccine resistance. (https://www.cbsnews.com/news/south-africa-covid-strain-resistance-antibodies-coronavirus-vaccine-latest-research/)
Contrary to the original theory of a cytokine storm (popularized by CYDY/Leronlimab without good scientific proof), more recent research has indicated that the SARS-CoV-2 infection triggers a dual mode of action with cell death pathways and inflammatory responses which may lead to severe lung damage in COVID-19 patients. (https://www.nature.com/articles/s41392-020-00334-0). The fact that Zyesami is both an inhibitor or apoptosis and a powerful anti-inflammatory medication makes this drug uniquely suited to treat COVID patients.
PHASE 3 RESULTS:
The recent phase 3 trial for VIP/Zyesami was based on the results of 196 patients. It was a randomized, placebo-controlled trial with identical drug and placebo infusion bags.
These patients received escalating doses of the IV medication in 3 separate doses. They were then followed for 28 days.
ClinicalTrials.org study information can be found here: https://clinicaltrials.gov/ct2/show/study/NCT...amp;rank=1
The results were STATISTICALLY SIGNIFICANT for 28 day hospital admission with 60 day results on respiratory failure and mortality pending (unblinded 2/22/21).
Secondary Endpoints were:
1.Improvement on NIAID Scale
2.Survival through day 28 and day 60
3.Time to ICU discharge
4.Time on ventilation (Time on mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen)
5.Time to extubation
6.Time to discharge alive
7.Multi-organ failure free days
Other Outcome Measures were:
1.Respiratory Distress while on mechanical ventilation (PaO2:FiO2 ratio)
2.Oxygenation index (Time Frame: Day 0 through day 28)
3. Improvement in chest x-ray (scored by RALES score)
4. Improvement in inflammatory markers (Improvement in IL-6, TNF alpha, and other inflammatory markers)
EAP CLINICAL TRIAL RESULTS:
Relief Therapeutics has enrolled more than 200 patients in their compassionate use (EAP) program. These patients were patients who were too sick for the Phase 3 trial. Patients who had multiple comorbidities such as: lung transplant patients, patients with lung cancer, p
from YH-00
Relief Therapeutics, a penny stock trading under RLFTF is a small Swiss biotech that owns the rights to synthetic vasoactive intestinal peptide (VIP). The substance is also known by the trademarked names, aviptadil, RLF-100 and Zyesami. VIP is a peptide. Peptides are small molecules which are produced by the body and have systemic effects. In proof that good things come from small packages, consider the fact that the most famous peptide is insulin.
As of 2/23/21, Relief Therapeutics and their profit-sharing partner, NeuroRx have announced positive data related to their recent phase 3 trial. The results were STATISTICALLY SIGNIFICANT for patients high flow O2. These patients get out of the hospital faster BY 10 DAYS! This means we now have an effective COVID 19 therapy for patients in the ICU. It improves oxygenation, gets them out of the hospital fast and prevents progression to mechanical ventilation.
Based on the favorable results, one can reasonably conclude that:
Submission of phase 3 data has already occurred to the FDA in anticipation of possible EUA
OWS has received a copy of this favorable phase 3 data with the expectation that their pending contract (30k initial treatment purchase and purchase of 100k treatments quarterly) may rapidly be approved.
Rapid adoption in ICUs nationwide can be anticipated given the improvement in survival, oxygenation, days on mechanical ventilation and days in the ICU overall
Peer reviewed publication of results in The Lancet and other journals
WHY IS VIP/Aviptadil/RLF-100/Zyesami SO GREAT AT TREATING COVID?
Well, for one, VIP has five separate mechanisms of action.
It directly inhibits viral replication
It has broad anti-inflammatory effects with decrease in II 6, cytokines and TNF
It causes surfactant production
It has direct bronchodilator effects to improve pulmonary blood-flow and increase the V/Q ratio (level of oxygenation)
Blocks apoptosis (cell death)
Additionally, VIP is highly effective at treating COVID because it is not dependent on the protein spike that most current vaccines work on. To this end, VIP efficacy is not affected by the current coronavirus mutations (London strain, South African strain, etc) which are beginning to demonstrate increased mortality and vaccine resistance. (https://www.cbsnews.com/news/south-africa-covid-strain-resistance-antibodies-coronavirus-vaccine-latest-research/)
Contrary to the original theory of a cytokine storm (popularized by CYDY/Leronlimab without good scientific proof), more recent research has indicated that the SARS-CoV-2 infection triggers a dual mode of action with cell death pathways and inflammatory responses which may lead to severe lung damage in COVID-19 patients. (https://www.nature.com/articles/s41392-020-00334-0). The fact that Zyesami is both an inhibitor or apoptosis and a powerful anti-inflammatory medication makes this drug uniquely suited to treat COVID patients.
PHASE 3 RESULTS:
The recent phase 3 trial for VIP/Zyesami was based on the results of 196 patients. It was a randomized, placebo-controlled trial with identical drug and placebo infusion bags.
These patients received escalating doses of the IV medication in 3 separate doses. They were then followed for 28 days.
ClinicalTrials.org study information can be found here: https://clinicaltrials.gov/ct2/show/study/NCT...amp;rank=1
The results were STATISTICALLY SIGNIFICANT for 28 day hospital admission with 60 day results on respiratory failure and mortality pending (unblinded 2/22/21).
Secondary Endpoints were:
1.Improvement on NIAID Scale
2.Survival through day 28 and day 60
3.Time to ICU discharge
4.Time on ventilation (Time on mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen)
5.Time to extubation
6.Time to discharge alive
7.Multi-organ failure free days
Other Outcome Measures were:
1.Respiratory Distress while on mechanical ventilation (PaO2:FiO2 ratio)
2.Oxygenation index (Time Frame: Day 0 through day 28)
3. Improvement in chest x-ray (scored by RALES score)
4. Improvement in inflammatory markers (Improvement in IL-6, TNF alpha, and other inflammatory markers)
EAP CLINICAL TRIAL RESULTS:
Relief Therapeutics has enrolled more than 200 patients in their compassionate use (EAP) program. These patients were patients who were too sick for the Phase 3 trial. Patients who had multiple comorbidities such as: lung transplant patients, patients with lung cancer, p
from YH-00
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
